Answers are grounded in this paper and cite their sources.
Posterior subcapsular cataract (PSC) was diagnosed in 9 out of 130 consecutive cases of rheumatoid arthritis. Seven of the 9 PSC patients had been treated with paramethasone, at least for some period of time. All the PSC patients had had long-term continuous corticosteroid therapy with total doses equal to or greater than 3 550 mg (mean 10 840 mg) prednisolone. All the patients in the material with a minimum total dose of 3 550 mg were analysed with respect to the various types of corticosteroids employed. Only 2 of 17 non-cataract patients had received paramethasone. Prednisolone was the commonest type of steroid in these patients. Two patients with non-PSC cataracts had been treated with paramethasone. The difference in the prevalence of PSC between the patients treated and those not treated with paramethasone is highly significant (p< 0.005) if the 2 patients with non-PSC cataract are excluded, and significant (p < 0.025) if the latter are included among the non-PSC patients. Moreover, an association between PSC and low-dosage therapy (< 10 prednisolone mg equivalent) was observed in the paramethasone-treated patients alone. The conclusions will be that paramethasone implies a greater risk of the complication PSC than does prednisolone in conventional equivalent doses and that there is a risk of PSC even at low-dosage paramethasone therapy, when administered continuously in rheumatoid arthritis for prolonged periods of time.
No takes yet. Share an insight, caveat, or question.
Gullberg et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: